Tasci, E. S. Et Al. 2024. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. EXPERT OPINION ON PHARMACOTHERAPY , vol.25, no.4 , 477-484.

Tasci, E. S., KUTLU, Y., ÖLMEZ, Ö. F., Mutlu, A. U., Gundogdu, Y., Seyyar, M., ... Sahin, E.(2024). Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. EXPERT OPINION ON PHARMACOTHERAPY , vol.25, no.4, 477-484.

Tasci, Elif Et Al. "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study," EXPERT OPINION ON PHARMACOTHERAPY , vol.25, no.4, 477-484, 2024

Tasci, Elif S. Et Al. "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study." EXPERT OPINION ON PHARMACOTHERAPY , vol.25, no.4, pp.477-484, 2024

Tasci, E. S. Et Al. (2024) . "Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study." EXPERT OPINION ON PHARMACOTHERAPY , vol.25, no.4, pp.477-484.

@article{article, author={Elif Senocak Tasci Et Al. }, title={Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study}, journal={EXPERT OPINION ON PHARMACOTHERAPY}, year=2024, pages={477-484} }